Intelgenx Technologs
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral fil… Read more
Intelgenx Technologs (IGXT) - Net Assets
Latest net assets as of March 2024: $-15.37 Million USD
Based on the latest financial reports, Intelgenx Technologs (IGXT) has net assets worth $-15.37 Million USD as of March 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.55 Million) and total liabilities ($21.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-15.37 Million |
| % of Total Assets | -234.67% |
| Annual Growth Rate | N/A |
| 5-Year Change | -4279.86% |
| 10-Year Change | -367.81% |
| Growth Volatility | 326.84 |
Intelgenx Technologs - Net Assets Trend (2006–2023)
This chart illustrates how Intelgenx Technologs's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Intelgenx Technologs (2006–2023)
The table below shows the annual net assets of Intelgenx Technologs from 2006 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-12.25 Million | -257.79% |
| 2022-12-31 | $-3.42 Million | -188.43% |
| 2021-12-31 | $3.87 Million | +506.19% |
| 2020-12-31 | $-953.00K | -425.26% |
| 2019-12-31 | $293.00K | -97.07% |
| 2018-12-31 | $9.99 Million | +160.83% |
| 2017-12-31 | $3.83 Million | -22.57% |
| 2016-12-31 | $4.95 Million | -11.13% |
| 2015-12-31 | $5.56 Million | +21.67% |
| 2014-12-31 | $4.57 Million | -8.69% |
| 2013-12-31 | $5.01 Million | +129.94% |
| 2012-12-31 | $2.18 Million | -44.21% |
| 2011-12-31 | $3.90 Million | +164.50% |
| 2010-12-31 | $1.48 Million | -31.57% |
| 2009-12-31 | $2.16 Million | +1156.98% |
| 2008-12-31 | $171.60K | -19.01% |
| 2007-12-31 | $211.87K | -35.42% |
| 2006-12-31 | $328.08K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Intelgenx Technologs's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7844511100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | % |
| Other Comprehensive Income | $-2.45 Million | % |
| Other Components | $68.66 Million | % |
| Total Equity | $-12.25 Million | 100.00% |
Intelgenx Technologs Competitors by Market Cap
The table below lists competitors of Intelgenx Technologs ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sunndal Sparebank
OL:SUNSB
|
$23.05 Million |
|
Minera Alamos Inc
OTCQX:MAIFF
|
$23.06 Million |
|
Lider Faktoring AS
IS:LIDFA
|
$23.06 Million |
|
Banco da Amazônia S.A
SA:BAZA3
|
$23.06 Million |
|
Tropical Canning (Thailand) Public Company Limited
BK:TC
|
$23.04 Million |
|
Revoil S.A
AT:REVOIL
|
$23.04 Million |
|
Kotra Industries Bhd
KLSE:0002
|
$23.04 Million |
|
Santam
JSE:SNT
|
$23.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Intelgenx Technologs's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -3,423,000 to -12,247,000, a change of -8,824,000.
- Net loss of 9,927,000 reduced equity.
- New share issuances of 2,970,000 increased equity.
- Other comprehensive income decreased equity by 219,000.
- Other factors decreased equity by 1,648,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.93 Million | -81.06% |
| Share Issuances | $2.97 Million | +24.25% |
| Other Comprehensive Income | $-219.00K | -1.79% |
| Other Changes | $-1.65 Million | -13.46% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Intelgenx Technologs's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $-0.01 | $0.17 | x |
| 2005-12-31 | $0.00 | $0.17 | x |
| 2006-12-31 | $0.02 | $0.17 | x |
| 2007-12-31 | $0.01 | $0.17 | x |
| 2008-12-31 | $0.01 | $0.17 | x |
| 2009-12-31 | $0.09 | $0.17 | x |
| 2010-12-31 | $0.04 | $0.17 | x |
| 2011-12-31 | $0.09 | $0.17 | x |
| 2012-12-31 | $0.04 | $0.17 | x |
| 2013-12-31 | $0.09 | $0.17 | x |
| 2014-12-31 | $0.07 | $0.17 | x |
| 2015-12-31 | $0.08 | $0.17 | x |
| 2016-12-31 | $0.08 | $0.17 | x |
| 2017-12-31 | $0.06 | $0.17 | x |
| 2018-12-31 | $0.13 | $0.17 | x |
| 2019-12-31 | $0.00 | $0.17 | x |
| 2020-12-31 | $-0.01 | $0.17 | x |
| 2021-12-31 | $0.03 | $0.17 | x |
| 2022-12-31 | $-0.02 | $0.17 | x |
| 2023-12-31 | $-0.07 | $0.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Intelgenx Technologs utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -955.44%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-370.10%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.70K |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.92K |
| 2006 | -238.09% | -293.77% | 0.41x | 1.98x | $-813.94K |
| 2007 | -519.58% | -131.77% | 0.66x | 6.00x | $-1.12 Million |
| 2008 | -1635.40% | -287.36% | 0.60x | 9.45x | $-2.82 Million |
| 2009 | -89.96% | -151.75% | 0.45x | 1.33x | $-2.16 Million |
| 2010 | -209.76% | -231.56% | 0.73x | 1.24x | $-3.24 Million |
| 2011 | -62.81% | -557.27% | 0.10x | 1.17x | $-2.84 Million |
| 2012 | -103.31% | -186.26% | 0.29x | 1.91x | $-2.47 Million |
| 2013 | -32.73% | -172.89% | 0.15x | 1.24x | $-2.14 Million |
| 2014 | -38.18% | -105.24% | 0.26x | 1.37x | $-2.20 Million |
| 2015 | 23.20% | 25.34% | 0.57x | 1.60x | $734.60K |
| 2016 | -23.86% | -22.61% | 0.41x | 2.59x | $-1.67 Million |
| 2017 | -79.68% | -58.73% | 0.40x | 3.43x | $-3.43 Million |
| 2018 | -101.21% | -554.17% | 0.09x | 2.00x | $-11.11 Million |
| 2019 | -4050.17% | -1599.33% | 0.07x | 37.61x | $-11.90 Million |
| 2020 | 0.00% | -534.07% | 0.14x | 0.00x | $-8.15 Million |
| 2021 | -240.56% | -606.64% | 0.09x | 4.63x | $-9.70 Million |
| 2022 | 0.00% | -1259.68% | 0.10x | 0.00x | $-11.62 Million |
| 2023 | 0.00% | -955.44% | 0.13x | 0.00x | $-8.70 Million |
Industry Comparison
This section compares Intelgenx Technologs's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Intelgenx Technologs (IGXT) | $-15.37 Million | 0.00% | N/A | $23.05 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |